Evidence map›Paper›PMID 26798526›Full record

ArticleCase reports in hematology2015

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia.

Manuel Molina, Sarvari Yellapragada, Martha Mims, Effie Rahman, Gustavo Rivero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manuel MolinaSt. Luke's Episcopal Hospital, Houston, TX 77030, USA.
Sarvari YellapragadaBaylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA; The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Martha MimsSt. Luke's Episcopal Hospital, Houston, TX 77030, USA; Baylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA; The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.
Effie RahmanBaylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA.
Gustavo RiveroSt. Luke's Episcopal Hospital, Houston, TX 77030, USA; Baylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA; The Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our primary aim was to identify potential risk factors and clinical outcome of azanucleoside induced pulmonary complications in patients with myelodysplastic syndrome (MDS) and Acute Myelogenous Leukemia (AML). We present an 89-year-old female with MDS derived AML who developed fatigability, hypoxemia, and bilateral lung infiltrates indicating interstitial lung disease after 11 cycles of azanucleoside. In addition, we describe a cohort of six MDS patients with fever, cough, dyspnea, and pulmonary infiltrates at early time point during azanucleoside treatment. Early and late onset of pulmonary manifestations suggest different pathogenic mechanisms. Brief azanucleoside discontinuation and steroids led to rapid improvement in symptoms.

Identifiers

PMID26798526
PMCPMC4698523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.